162 related articles for article (PubMed ID: 33925547)
1. Identification of CRYAB
Augustus M; Pineau D; Aimond F; Azar S; Lecca D; Scamps F; Muxel S; Darlix A; Ritchie W; Gozé C; Rigau V; Duffau H; Hugnot JP
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33925547
[TBL] [Abstract][Full Text] [Related]
2. Cellular and molecular characterization of IDH1-mutated diffuse low grade gliomas reveals tumor heterogeneity and absence of EGFR/PDGFRα activation.
Azar S; Leventoux N; Ripoll C; Rigau V; Gozé C; Lorcy F; Bauchet L; Duffau H; Guichet PO; Rothhut B; Hugnot JP
Glia; 2018 Feb; 66(2):239-255. PubMed ID: 29027701
[TBL] [Abstract][Full Text] [Related]
3. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
[TBL] [Abstract][Full Text] [Related]
4. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.
Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A
Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617
[TBL] [Abstract][Full Text] [Related]
5. PDGFRA gain in low-grade diffuse gliomas.
Motomura K; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Nakazato Y; Tanaka Y; Nonoguchi N; Pierscianek D; Kim YH; Mariani L; Vital A; Perry A; Ohgaki H
J Neuropathol Exp Neurol; 2013 Jan; 72(1):61-6. PubMed ID: 23242283
[TBL] [Abstract][Full Text] [Related]
6. ZEB1 expression is increased in IDH1-mutant lower-grade gliomas.
Nesvick CL; Zhang C; Edwards NA; Montgomery BK; Lee M; Yang C; Wang H; Zhu D; Heiss JD; Merrill MJ; Ray-Chaudhury A; Zhuang Z
J Neurooncol; 2016 Oct; 130(1):111-122. PubMed ID: 27568035
[TBL] [Abstract][Full Text] [Related]
7. Biomarker-driven diagnosis of diffuse gliomas.
Appin CL; Brat DJ
Mol Aspects Med; 2015 Nov; 45():87-96. PubMed ID: 26004297
[TBL] [Abstract][Full Text] [Related]
8. Molecular signatures classify astrocytic gliomas by IDH1 mutation status.
Toedt G; Barbus S; Wolter M; Felsberg J; Tews B; Blond F; Sabel MC; Hofmann S; Becker N; Hartmann C; Ohgaki H; von Deimling A; Wiestler OD; Hahn M; Lichter P; Reifenberger G; Radlwimmer B
Int J Cancer; 2011 Mar; 128(5):1095-103. PubMed ID: 20473936
[TBL] [Abstract][Full Text] [Related]
9. GABA, glutamine, glutamate oxidation and succinic semialdehyde dehydrogenase expression in human gliomas.
Hujber Z; Horváth G; Petővári G; Krencz I; Dankó T; Mészáros K; Rajnai H; Szoboszlai N; Leenders WPJ; Jeney A; Tretter L; Sebestyén A
J Exp Clin Cancer Res; 2018 Nov; 37(1):271. PubMed ID: 30404651
[TBL] [Abstract][Full Text] [Related]
10. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.
Ligon KL; Alberta JA; Kho AT; Weiss J; Kwaan MR; Nutt CL; Louis DN; Stiles CD; Rowitch DH
J Neuropathol Exp Neurol; 2004 May; 63(5):499-509. PubMed ID: 15198128
[TBL] [Abstract][Full Text] [Related]
11. Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma.
Yang R; Zhao Y; Gu Y; Yang Y; Gao X; Yuan Y; Xiao L; Zhang J; Sun C; Yang H; Qin J; Li J; Zhang F; Zhang L; Ye J
Oncogene; 2020 Oct; 39(40):6340-6353. PubMed ID: 32855525
[TBL] [Abstract][Full Text] [Related]
12. Molecular genetics of gliomas.
Appin CL; Brat DJ
Cancer J; 2014; 20(1):66-72. PubMed ID: 24445767
[TBL] [Abstract][Full Text] [Related]
13. Autocrine BMP4 Signaling Enhances Tumor Aggressiveness via Promoting Wnt/β-Catenin Signaling in IDH1-mutant Gliomas.
Zhou Y; Liu Y; Zhang J; Yu D; Li A; Song H; Zhang W; Davis D; Gilbert MR; Liu F; Yang C
Transl Oncol; 2020 Feb; 13(2):125-134. PubMed ID: 31865175
[TBL] [Abstract][Full Text] [Related]
14. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A
Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337
[TBL] [Abstract][Full Text] [Related]
15. Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma.
Chen YY; Ho HL; Lin SC; Hsu CY; Ho DM
Neurosurgery; 2019 Sep; 85(3):335-342. PubMed ID: 30113684
[TBL] [Abstract][Full Text] [Related]
16. Prediction of
Park YW; Han K; Ahn SS; Bae S; Choi YS; Chang JH; Kim SH; Kang SG; Lee SK
AJNR Am J Neuroradiol; 2018 Jan; 39(1):37-42. PubMed ID: 29122763
[TBL] [Abstract][Full Text] [Related]
17. Expression of oligodendrocyte lineage genes in oligodendroglial and astrocytic gliomas.
Riemenschneider MJ; Koy TH; Reifenberger G
Acta Neuropathol; 2004 Mar; 107(3):277-82. PubMed ID: 14730454
[TBL] [Abstract][Full Text] [Related]
18. Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma.
Sun C; Xiao L; Zhao Y; Shi J; Yuan Y; Gu Y; Zhang F; Gao X; Yang Y; Yang R; Qin J; Zhang J; Wang C; Wang Y; Wang Z; Hu P; Chang T; Wang L; Wang G; Chen H; Li Z; Ye J
Transl Oncol; 2020 Apr; 13(4):100758. PubMed ID: 32208352
[TBL] [Abstract][Full Text] [Related]
19. Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers.
Figarella-Branger D; Maues de Paula A; Colin C; Bouvier C
Rev Neurol (Paris); 2011 Oct; 167(10):683-90. PubMed ID: 21889777
[TBL] [Abstract][Full Text] [Related]
20. Bone morphogenetic protein signaling and olig1/2 interact to regulate the differentiation and maturation of adult oligodendrocyte precursor cells.
Cheng X; Wang Y; He Q; Qiu M; Whittemore SR; Cao Q
Stem Cells; 2007 Dec; 25(12):3204-14. PubMed ID: 17872503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
